{"version":"1.0","type":"link","title":"Healthcare costs and health outcomes analysis of neoadjuvant Trastuzumab therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer.","author_name":"Jalali A 외","author_url":"https://prs-insight.online/author/Jalali%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/74641","thumbnail_width":1200,"thumbnail_height":630}